酶联免疫斑点法在重症药疹致敏药物鉴定中的应用

doi:10.3760/cma.j.issn.0412-4030.2019.06.015

Abstract

Abstract: 【Abstract】 Early identification of culprit drugs is crucial for the treatment and prevention of severe drug eruptions. At present, no accurate and effective methods are available for identifying the culprit drugs in severe drug eruptions. Commonly used tests include patch test, lymphocyte transformation test and so on. However, low sensitivity and specificity limit their clinical application. Enzyme-linked immunospot assay, an in vitro technique, can identify culprit drugs in cutaneous adverse drug reactions by detecting cytokines secreted by drug-specific T lymphocytes. It has high sensitivity and specificity in patients with severe drug eruptions, and can be carried out during the acute stage of disease or among immunocompromised patients. Therefore, enzyme-linked immunospot assay may be an effective method for identifying culprit drugs in severe drug eruptions.

Key words: Drug eruptions, Enzyme-linked immunospot assay, Interferon-gamma release tests, Sensitivity and specificity, Culprit drugs

Gao Xuemei, Zhang Xingqi, Wang Fang. Application of enzyme?linked immunospot assay in the identification of culprit drugs in severe drug eruptions[J]. Chinese Journal of Dermatology, 2019, 52(6): 436-439.doi:10.3760/cma.j.issn.0412-4030.2019.06.015

References ［27］

［1］	Duong TA, Valeyrie⁃Allanore L, Wolkenstein P, et al. Severe cutaneous adverse reactions to drugs［J］. Lancet, 2017,390（10106）:1996⁃2011. doi: 10.1016/S0140⁃6736（16）30378⁃6.
［2］	Hoetzenecker W, Nägeli M, Mehra ET, et al. Adverse cutaneous drug eruptions: current understanding［J］. Semin Immunopathol, 2016,38（1）:75⁃86. doi: 10.1007/s00281⁃015⁃0540⁃2.
［3］	Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions［J］. J Dermatol, 2016,43（7）:758⁃766. doi: 10.1111/jde. 2016.43.issue⁃7.
［4］	Peter JG, Lehloenya R, Dlamini S, et al. Severe delayed cutaneous and systemic reactions to drugs: a global perspective on the science and art of current practice［J］. J Allergy Clin Immunol Pract, 2017,5（3）:547⁃563. doi: 10.1016/j.jaip.2017.01. 025.
［5］	Beeler A, Engler O, Gerber BO, et al. Long⁃lasting reactivity and high frequency of drug⁃specific T cells after severe systemic drug hypersensitivity reactions［J］. J Allergy Clin Immunol, 2006,117（2）:455⁃462. doi: 10.1016/j.jaci.2005.10.030.
［6］	Wang F, Cai R, He D, et al. Serum IFN⁃γ⁃inducible chemokines CXCL9 and CXCL10 are elevated in non⁃immediate drug hypersensitivity reactions［J］. Asian Pac J Allergy Immunol, 2016,34（3）:236⁃241. doi: 10.12932/AP0679
［7］	Czerkinsky CC, Nilsson LA, Nygren H, et al. A solid⁃phase enzyme⁃linked immunospot （ELISPOT） assay for enumeration of specific antibody⁃secreting cells［J］. J Immunol Methods, 1983,65（1⁃2）:109⁃121. doi: 10.1016/0022⁃1759（83）90308⁃3.
［8］	Su SC, Chung WH. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions［J］. Toxins （Basel）, 2014,6（1）:194⁃210. doi: 10.3390/toxins6010194.
［9］	Polak ME, Belgi G, McGuire C, et al. In vitro diagnostic assays are effective during the acute phase of delayed⁃type drug hypersensitivity reactions［J］. Br J Dermatol, 2013,168（3）:539⁃549. doi: 10.1111/bjd.2013.168.issue⁃3.
［10］	Haw WY, Polak ME, McGuire C, et al. In vitro rapid diagnostic tests for severe drug hypersensitivity reactions in children［J］. Ann Allergy Asthma Immunol, 2016,117（1）:61⁃66. doi: 10.1016/j.anai.2016.04.017.
［11］	Klaewsongkram J, Thantiworasit P, Suthumchai N, et al. In vitro test to confirm diagnosis of allopurinol⁃induced severe cutaneous adverse reactions［J］. Br J Dermatol, 2016,175（5）:994⁃1002. doi: 10.1111/bjd.2016.175.issue⁃5.
［12］	Porebski G, Pecaric⁃Petkovic T, Groux⁃Keller M, et al. In vitro drug causality assessment in Stevens⁃Johnson syndrome ⁃ alterna⁃tives for lymphocyte transformation test［J］. Clin Exp Allergy, 2013,43（9）:1027⁃1037. doi: 10.1111/cea.2013.43.issue⁃9.
［13］	Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. Nat Med, 2008,14（12）:1343⁃1350. doi: 10.1038/nm.1884.
［14］	Abe R, Yoshioka N, Murata J, et al. Granulysin as a marker for early diagnosis of the Stevens⁃Johnson syndrome［J］. Ann Intern Med, 2009,151（7）:514⁃515. doi: 10.7326/0003⁃4819⁃151⁃7⁃200910060⁃00016.
［15］	Wang F, Ye Y, Luo ZY, et al. Diverse of TNF⁃α and CCL27 in serum and blister of Stevens⁃Johnson syndrome/toxic epidermal necrolysis［J］. Clin Transl Allergy, 2018,8:12. doi: 10. 1186/s13601⁃018⁃0199⁃6.
［16］	Ogawa K, Morito H, Hasegawa A, et al. Elevated serum thymus and activation⁃regulated chemokine （TARCCCL17） relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms （DRESS）drug⁃induced hypersensitivity syndrome （DIHS）［J］. Br J Dermatol, 2014,171（2）:425⁃427. doi: 10.1111/bjd.12948.
［17］	White KD, Chung WH, Hung SI, et al. Evolving models of the immunopathogenesis of T cell⁃mediated drug allergy: the role of host, pathogens, and drug response［J］. J Allergy Clin Immunol, 2015,136（2）:219⁃234. doi: 10.1016/j.jaci.2015.05.050.
［18］	Esser S, Jablonka R, Heinemann FM, et al. Detection of abacavir hypersensitivity by ELISpot method［J］. Inflamm Allergy Drug Targets, 2012,11（3）:227⁃234. doi: 10.2174/187152812800392751.
［19］	Gibson A, Ogese M, Sullivan A, et al. Negative regulation by PD⁃L1 during drug⁃specific priming of IL⁃22⁃secreting T cells and the influence of PD⁃1 on effector T cell function［J］. J Immunol,2014,192（6）:2611⁃2621. doi: 10.4049/jimmunol.1302720.
［20］	Kato K, Kawase A, Azukizawa H, et al. Novel interferon⁃γ enzyme⁃linked immunoSpot assay using activated cells for identifying hypersensitivity⁃inducing drug culprits［J］. J Dermatol Sci, 2017,86（3）:222⁃229. doi: 10.1016/j.jdermsci.2017.03.007.
［21］	Adler NR, Aung AK, Ergen EN, et al. Recent advances in the understanding of severe cutaneous adverse reactions［J］. Br J Dermatol, 2017,177（5）:1234⁃1247. doi: 10.1111/bjd.15423.
［22］	Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions［J］. Br J Dermatol, 2013,168（3）:555⁃562. doi: 10.1111/bjd.2013.168.issue⁃3.
［23］	Wolkenstein P, Chosidow O, Flechet ML, et al. Patch testing in severe cutaneous adverse drug reactions,including Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. Contact Dermatitis, 1996,35（4）:234⁃236. doi: 10.1111/j.1600⁃0536.1996. tb02364.x.
［24］	Agache I, Bilo M, Braunstahl GJ, et al. In vivo diagnosis of allergic diseases⁃⁃allergen provocation tests［J］. Allergy, 2015,70（4）:355⁃365. doi: 10.1111/all.2015.70.issue⁃4.
［25］	Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity［J］. Allergy, 2004,59（8）:809⁃820. doi: 10.1111/all.2004.59.issue⁃8.
［26］	Cabanas R, Calderon O, Ramirez E, et al. Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment［J］. Clin Exp Allergy, 2018,48（3）:325⁃333. doi: 10.1111/cea. 2018.48.issue⁃3.
［27］	Trubiano JA, Strautins K, Redwood AJ, et al. The combined utility of ex vivo IFN⁃gamma release enzyme⁃linked immunoSpot assay and in vivo skin testing in patients with antibiotic⁃associated severe cutaneous adverse reactions［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1287⁃1296.e1. doi: 10. 1016/j.jaip. 2017.09.004.

[1]	Xu Wen, Ling Xin, Shi Xin, Wan Congchong, Dai Caihong, Yang Zhigang, Chen Lingling. Evaluation of the applicability of the Zhang′s diagnostic criteria for atopic dermatitis in adolescents and adults from southern Jiangsu [J]. Chinese Journal of Dermatology, 2022, 55(12): 1084-1088.
[2]	Long Hai, Jiang Li, Qiu Yueqi, Yao Nan, Liu Licong, Xie Yuming, Xiong Feng, Tan Siqi, Kuang Qiqi, You Ruixuan, Chai Ke, Luo Xin, Long Haojun, Xin Yue, Guo Ziyu, Wang Jiaqi, Tan Yixin, Zhang Qing, Zhang Guiying, Li Yaping, Su Yuwen, Xiao Rong, Lu Qianjin, . Clinical analysis of 1 057 patients with critical illnesses in a dermatological ward [J]. Chinese Journal of Dermatology, 2021, 54(9): 790-797.
[3]	Adverse Drug Reaction Research Center of Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2021, 54(5): 376-381.
[4]	Xu Beilei, Yao Xu. Detection methods for allergen-specific T cells [J]. Chinese Journal of Dermatology, 2021, 54(4): 364-367.
[5]	Kang Li, Liu Yan, Zheng Yunyan, Ju Mei, Zhang Yamei, Bi Zhigang, Lu Guiqing. Clinical analysis of cutaneous delayed-type hypersensitivity caused by injection of equine tetanus antitoxin or equine anti-tetanus immunoglobulin F（ab′）₂ [J]. Chinese Journal of Dermatology, 2021, 54(3): 226-228.
[6]	Deng Sisi, Wang Huan, Yu Nanlan, Li Song, Song Zhiqiang. Clinical analysis of 45 cases of drug-induced hypersensitivity syndrome [J]. Chinese Journal of Dermatology, 2021, 54(2): 127-130.
[7]	Yao Cuiling, Wang Zihan, Hu Jingjing, Gao Yu, Ding Changling. Analysis of fever and drug-induced liver injury in 63 patients with severe drug eruptions [J]. Chinese Journal of Dermatology, 2021, 54(11): 984-989.
[8]	Xiao Yang, Zhang Xiaoguang. Lamotrigine-induced drug eruption [J]. Chinese Journal of Dermatology, 2021, 54(10): 927-930.
[9]	Yu-Ping HUO. Acute generalized exanthematous pustulosis caused by lincomycin: a case report [J]. Chinese Journal of Dermatology, 2018, 51(7): 531-533.
[10]	. CD4+ and CD8+ T cell levels as well as clinical features in HIV-positive patients with drug eruption [J]. Chinese Journal of Dermatology, 2015, 48(12): 853-856.
[11]	. Preliminary study on Epstein-Barr virus infection in patients with drug eruption [J]. Chinese Journal of Dermatology, 2009, 42(8): 556-559.
[12]	. Comparison analysis of severe drug eruption between children and adults [J]. Chinese Journal of Dermatology, 2009, 42(11): 782-783.
[13]	ZHOU Ping-yu, Yang Lian-juan, LU Hai-kong, GU Zhi-ying, XU Li-ying. Clinical study of Zhenju Jiangya Pian-induced photosensitive drug eruptions [J]. Chinese Journal of Dermatology, 2007, 40(12): 746-747.
[14]	NIU Hong-xi, GENG Long, SHANG Ying-bin, XU Yuan-yuan, SONG Fang-ji, CHEN Hong-duo. Clinical analysis of 191 cases of severe drug eruptions [J]. Chinese Journal of Dermatology, 2006, 39(9): 530-532.
[15]	HE Zhi-xin, GAN Ge, WANG Bao-xi. Clinical analysis of 539 patients with drug eruption [J]. Chinese Journal of Dermatology, 2006, 39(12): 703-705.

Application of enzyme?linked immunospot assay in the identification of culprit drugs in severe drug eruptions

PDF

Knowledge

Abstract

Cite this article

share this article

References ［27］

Related Articles 15

Metrics

Comments

Recommended 10